Nod cg prkdcscid j mice

BRAF-mutant melanoma cell lines, WM1341D, WM983B, 1205Lu, WM852, WM793, WM35, WM167 (gifted from Dr. Meenhard Herlyn, The Wistar Institute), A375 (purchased from ATCC), and 1205Lu derivatives, 1205Lu-M1 and 1205Lu-M2 (generated in this study), were maintained in DMEM with 1% penicillin-streptomycin, 1% L-glutamine, and 10% (v/v) FBS. BRAF-wildtype MeWo and NRAS-mutant SKMEL2 cell lines (both purchased from ATCC) were also maintained in the same culture medium as the BRAF-mutant cells. Cells were grown at 37°C under a humidified atmosphere of 5% CO_2. Cell lines (WM793, 1205Lu, 1205Lu-M1, and 1205Lu-M2) was authenticated by STR profiling (Genetica Cell Line Testing, LabCorp) and confirmed human origin.
In vivo mouse experiments were performed in compliance with an animal protocol approved by the Institutional Animal Care and Use Committee at the Center for Discovery and Innovation, Hackensack Meridian Health. Animal experiments were carried out with 10-12 weeks old NOD/SCID (NOD.Cg-Prkdc^scid/J) mice purchased from The Jackson Laboratory (Bar Harbor, ME) and maintained under standard pathogen free conditions.

All animal experiments described in this study were approved by the Institutional Animal Care and Use Committee (IACUC) at the Salk Institute for Biological Studies (12-00022), and the University of California San Diego (S12201), and were conducted in accordance with the National Institutes of Health’s Guide for the Care and Use of Laboratory Animals. Male and female mice were group-housed when possible with up to 5 mice per cage, under standard conditions, and kept on a 12-h light/dark cycle with ad libitum access to food and water. Immune-deficient NOD.Cg-Prkdc^scid/J mice, aged 6–8 weeks, were purchased from Jackson Laboratories (JAX Stock: 001303) or were generated in our lab by breeding. In the majority of the experiments, female mice 6–10 weeks of age were used.